Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study

• Main Authors: Lawrence Mbuagbaw, Clémence Ongolo-Zogo, Olivia C. Mendoza, Babalwa Zani, Frederick Morfaw, Agatha Nyambi, Annie Wang, Michel Kiflen, Hussein El-Kechen, Alvin Leenus, Mark Youssef, Nadia Rehman, Lucas Hermans, Virginia MacDonald, Silvia Bertagnolio
• Format: Article
• Language: English
• Published: BMC 2021-04-01
• Series: BMC Medical Research Methodology
• Subjects: HIV; Pre-treatment drug resistance; Reporting; Guidelines
• Online Access: https://doi.org/10.1186/s12874-021-01258-1

Abstract Background The expansion of access to antiretroviral therapy (ART) has been accompanied by an increase in pre-treatment drug resistance (PDR). While it is critical to monitor the increasing prevalence of PDR across countries and populations to inform optimal regimen selection, the completeness of reporting is often suboptimal, limiting the interpretation and generalizability of the results. Indeed, there is no formal guidance on how studies investigating the prevalence of drug resistance should be reported. Thus, we sought to determine the completeness of reporting in studies of PDR and the factors associated with sub-optimal reporting to ascertain the need for guidelines. Methods As part of a systematic review on the global prevalence of PDR in key populations (men who have sex with men, sex workers, transgender people, people who inject drugs and people in prisons), we searched 10 electronic databases until January 2019. We extracted information on selected study characteristics useful for interpreting prevalence data. Data were extracted in duplicate. Analyses of variance and correlation were used to explore factors that may explain the number of items reported. Results We found 650 studies of which 387 were screened as full text and 234 were deemed eligible. The included studies were published between 1997 and 2019 and included a median of 239 (quartile 1 = 101; quartile 3 = 778) participants. Most studies originated from high-income countries (125/234; 53.0%). Of 23 relevant data items, including study design, setting, participant sociodemographic characteristics, HIV risk factors, type of resistance test conducted, definition of resistance, the mean (standard deviation) number of items reported was 13 (2.2). We found that more items were reported in studies published more recently (r = 0.20; p < 0.002) and in studies at low risk of bias (F [2231] = 8.142; p < 0.001). Conclusions Incomplete reporting in studies on PDR makes characterising levels of PDR in subpopulations across countries challenging. Hence, guidelines are needed to define a minimum set of variables to be included in such studies.